NDAORALTABLET, FOR SUSPENSIONPriority Review
Approved
Aug 2012
Lifecycle
Peak
Competitive Pressure
45/100
Clinical Trials
21
Mechanism of Action
Protein Kinase Inhibitors
Pharmacologic Class:
Kinase Inhibitor
Indications (15)
older with TSCpostmenopausal women with advanced hormone receptor-positiveHER2-negative breast cancer in combination with exemestaneafter failure of treatment with letrozoleanastrozolelocally advancedmetastatic diseasewell-differentiatednon-functional NET of gastrointestinal (GI)lung origin with unresectablesorafenibnot requiring immediate surgeryolder with TSC for the treatment of SEGAbreast cancerrenal cell carcinoma
Clinical Trials (5)
REsorbable SCaffolds With everolimUs-Elution for the Treatment of Infrapopliteal Artery Disease in Patients With Chronic Limb-threatening Ischemia
Started Apr 2026
400 enrolled
Chronic Limb Threatening IschemiaChronic Limb-Threatening Ischemia
To Evaluate the Performance and Safety of RisoR Crest Everolimus Eluting Coronary Stent System
Started Aug 2025
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
Started Jul 2025
440 enrolled
Pancreatic Neuroendocrine Tumor (pNET)Extra-Pancreatic Neuroendocrine Tumor (epNET)
An Open-Label, Single-Arm Exploratory Clinical Study of Everolimus for the Treatment of Vascular Malformations
Started Jul 2025
Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.
Started Dec 2024
240 enrolled
Advanced Breast CancerER-positive Breast CancerHER2-negative Breast Cancer+1 more